Recent News

• 06.03.2026 - LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
• 06.01.2026 - LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
• 05.14.2026 - LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
• 04.13.2026 - Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
• 03.31.2026 - LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Recent Filings

• 06.01.2026 - 8-K Current report
• 06.01.2026 - EX-99.1 EX-99.1
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 3 Initial statement of beneficial ownership of securities
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.17.2026 - 8-K Current report